Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631278 | 1.00 | HCRTR1 (0.40) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL4718438 | 0.91 | ALDH1A1 (0.40) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL4829848 | 0.91 | ALDH1A1 (0.40) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL4722964 | 0.91 | ALDH1A1 (0.40) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL4719446 | 0.87 | FFAR4 (0.35) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL5631276 | 0.87 | FFAR4 (0.35) | HCRTR1HCRTR2FFAR4HSD11B1ALDH1A1 | |
| SCHEMBL4718410 | 0.83 | HSD11B1 (0.39) | FFAR4HSD11B1BACE1 | |
| SCHEMBL5630400 | 0.83 | HSD11B1 (0.39) | FFAR4HSD11B1BACE1 | |
| SCHEMBL4824424 | 0.83 | HSD11B1 (0.36) | HCRTR1HCRTR2HSD11B1BACE1PDE4A | |
| SCHEMBL4721479 | 0.83 | HSD11B1 (0.36) | HCRTR1HCRTR2HSD11B1BACE1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| EP-1957494-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | claimed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | claimed |
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | HCRTR1 4094/4885HCRTR2 4496/4885FFAR4 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.